Endeavor Venture Fund & Venture Studio

NOTEWORTHY EMERGING COMPANIES NEURALINK / Elon Musk Neuralink, the Elon Musk-founded company developing implantable chips that can read brain waves, has raised an additional $43 million in venture capital and has raised a total of $551.31 million Neuralink recently received approval from an independent institutional review board and its hospital site to begin recruiting for human clinical trials. Neuralink is a pioneering neurotechnology enterprise specializing in the development of Brain-Computer Interface (BCI) technologies. These technologies facilitate a direct communication pathway between the human brain and external devices or computer systems through brain implantable connections. The device provides a generalized brain interface to restore autonomy to those with unmet medical needs via computer assisted interfaces with the user’s anatomy and physiology. #neuralink #AI #startups #endeavorventurefunds #drmartinalexandergershon #betterhealth Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH

Endeavor Venture Fund & Venture Studio our review committee sees over 200 pitch decks per month What do they look for? What every founder should know! Please send your deck to our review committee if you are a digital health company in EHR, radiology, pathology, precision medicine, personalized medicine, drug discovery, AI enabled devices or diagnostics, mental health [email protected] Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH

#jpm2024 J.P. Morgan Healthcare Conference was a tremendous week for Endeavor Venture Fund & Venture Studio solidifying new investor and strategic partnerships, signing new engagements with emerging companies, and taking the pulse of the healthcare community leadership Thank you Simon Gisby for your insightful comments about the vital role leadership, partnership, and collaboration play in the sustainable growth of emerging companies. It was a hour of terrific discussion addressing how important it is for Founders to development leadership toolkits to build teams that can adapt and pivot as they are required to address the problems of industry when integrating innovation into large enterprise ecosystems. It’s especially important in this challenging risk off environment to have partners that can drive the needed distribution and growth as companies look to scale globally. #jpm2024 #healthcare #lifesciences #investing #leadership #healthcareai #digitalhealth #endeavorventurefunds #drmartinalexandergershon Dr. D. Martin Alexander Gershon, MD, JD, MPH Endeavor Venture Fund & Venture Studio Deloitte Simon Gisby

Endeavor Venture Fund & Venture Studio is thrilled to be asked to advise and support the The President’s Office and Life Sciences team at NYCEDC (NY Economic Development Corporation) Venture Capital Team The team held an advisory meeting last week that was a grest opportunity to: Connect with the broad network of investors in life sciences in the NYC Encourage support to develop a pipeline of investment in companies for key EDC programs Inform the NYEDC life sciences engagement strategy team Generate actionable insight from VC on long-term plans to grow and build healthcare companies in NYC With the help of NYEDC NYC’s life sciences assets now include: Nine major academic medical centers $2.0 billion in annual National Institutes of Health (NIH) awards in 2020—an all-time high 7,000+ graduate students and postdocs at universities A 400 percent increase in private venture capital funding for the industry from 2016 to 2018 The largest biotech workforce in the country Six incubators to support early-stage life sciences companies I’m looking forward to engaging the Endeavor Venture Fund & Venture Studio ecosystem in the NYEDC growth strategies for digital healthcare companies! Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH Ali Mostashari, Ph.D Andrew Gostine, MD, MBA Peter Durlach David H Berger, MD, MHCM Michael Bouton Erik Lium Lawrence Vernaglia Shabbi Khan David Kantaros Ping Yeh Ashmita Kumar

Thrilled to be invited to participate in this terrific Forbes Investor Event in NYC! Forbes organzied another remarkable event with the world’s most influential dealmakers, financial titans, investors and market movers with over $20 trillion assets under management for high-level conversations on the most critical issues impacting our economy and markets today. Thrilled to participate ! Dr. D. Martin Alexander Gershon, MD, JD, MPH Endeavor Venture Fund & Venture Studio Mayan Katz David H Berger, MD, MHCM Danielle Solar Jobby John Ashmita Kumar Jenny M Fernandez, MBA, 费 珍妮 Andrew Gostine, MD, MBA Steve Ramsay

. At different funding stages, investors look for: Pre-Seed - concept validation, Seed - initial product-market fit, Series A - solid revenue growth, Series B - growing market share, and Series C+ - market leadership. Understanding these expectations is key to successful fundraising. To validate a startup concept, it's essential to understand the market and refine your idea based on feedback. Start by identifying your market, evaluating the need for your product or service, and then refine your concept with insights from industry experts and potential first customers. This approach ensures your startup idea is not only innovative but also viable in the market. To refine a startup idea, consider following a structured approach: Define your product/service, identify your target market, establish a unique identity, develop mission & vision, and create actionable plans. This method ensures a comprehensive refinement process, addressing key aspects that contribute to a startup's success. Achieving product-market fit is crucial for startups. It involves deeply understanding your target audience and ensuring your product solves a real problem for them. Given your expertise in AI & Digital Health Innovation, focusing on how your solutions meet specific healthcare needs, such as improving patient outcomes or streamlining healthcare processes, can guide you towards achieving product-market fit. For example, leveraging your knowledge in cognitive neuroscience could help develop AI solutions that personalize patient care, aligning product capabilities with market needs For more information contact [email protected] And join our investor deal making summit July 17th! HEALTHCARE AI AND TECHNOLOGY INVESTOR DEAL MAKING SUMMIT JULY 17th Live / Boston and Virtual https://lu.ma/f1mt0ziq Keynote Speaker: Peter Durlach, Microsoft Chief Strategy Officer, Healthcare and Life Sciences Closing Remarks: Jim Rogers, Board of Directors Mayo Collaborative Services, Chief Business Development Officer and Senior Administrator Generative AI, Mayo Clinic Summit Chairman: Dr. Martin Alexander Gershon, Managing Partner, Endeavor Venture Funds White House CancerX Moonshot Advisor https://lnkd.in/efzuTzG8 [email protected]

NOTEWORTHY COMPANIES IN AI Scale AI Secures $1 Billion in Funding, Paving the Way for Future AI Advancements Scale AI, recognized as the "data foundry for AI," has secured a $1 billion funding round, elevating the company’s valuation to $14 billion. Led by venture capital firm Accel, the round also saw significant contributions from Y Combinator, Index Ventures, Founders Fund, Nvidia, and Tiger Global Management. New investors include Cisco Investments, Intel Capital, AMD Ventures, Amazon, and Meta. As interest in generative AI continues to surge, enterprises are increasingly prioritizing high-quality training data for optimal AI model performance. Scale AI, headquartered in San Francisco, has been pioneering the generation of well-annotated training data long before the debut of ChatGPT in late 2022. The company excels in creating synthetic training data and annotated data, drawing on expert input from specialized fields such as physics. Looking ahead, Scale AI plans to leverage the new funding to significantly expand the production of AI training data, meeting the growing demand. The company also aims to advance its capabilities in helping enterprises evaluate and refine their AI models, positioning itself as a crucial player in the evolving AI landscape. Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH Andrew Gostine, MD, MBA Vibhor Gupta Sally Ann Frank Ping Yeh Ashmita Kumar Randall Stanicky Lawrence Vernaglia Rainer Strohmenger Elia Stupka Danielle Solar Rebecca Miksad, MD, MMS, MPH Nikhil Pradhan Geof Hannigan, PhD Alireza Masrour David Rhew, M.D. Aaron Gani

Thrilled to be Chairing the AI Healthcare Track at LSX World Congress this week in London! As part of this great event Endeavor is hosting a neworking and investor evening at British Telecom and then breakfast at Goodwin. Pepper Bio Co-Founder Jon (Yu) Hu will present to 20 venture capital investors and tell a remarkable story of how AI and ML are driving new opportunities to identify pharmaceutical assets and bring them to commercial markets in record time.(see video of Samantha Dale Strasser Co-Founder) Pepper Bio is in-licensing 4 phase 2 drug candidates in a groundbreaking move using advanced technologies to improve the predictive value and commercialization success roadmap. The future of drug discovery is here, now! Back by Endeavor, Merck, Northpond, McKesson, Microsoft and other world class investors and strategics, the company is poised to breakout in 2024-2025. Join us at our event at Goodwin in their new London offices, Endeavor will host 30 VIP investors, strategics and companies in a breakfast that offers a look into the future of digital technologies that are reshaping the healthcare world! Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH Samantha Dale Strasser Jon (Yu) Hu Ping Yeh Agata Maria Bendik Vibhor Gupta Sally Ann Frank David Rhew, M.D. Antonio Sánchez-Cordero Karim ReFaey Kevin Liu Zhiqi Ding Michal Zurawski, PhD Elliot Parnham Agata Maria Bendik Polina S.

Great spending time with so many of the smartest investing minds in the business at Sohn 2024. Healthcare innovation and AI important themes which we are squarely focused on at Click Therapeutics, Inc. Dr. D. Martin Alexander Gershon, MD, JD, MPH and Jenny M Fernandez, MBA, 费 珍妮 from Endeavor Venture Fund & Venture Studio always great to spend time with you. #sohn2024

Thrilled to be asked to join this fantastic group of prominent leaders and innovators in the American Medical Association Innovation Network! #innovation #entrepreneurship #venturecapital #AMA #drmartinalexandergershon #endeavorventurefunds Endeavor Venture Fund & Venture Studio Dr. D. Martin Alexander Gershon, MD, JD, MPH